{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:40:07Z","timestamp":1787499607875,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":225,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intraperitoneal chemotherapy using paclitaxel is considered an experimental approach for treating peritoneal carcinomatosis. This study aimed to determine the recommended dose, and to evaluate the clinical efficacy and safety, of the combination of intravenous gemcitabine, intravenous nab-paclitaxel and intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The frequencies of dose-limiting toxicities were evaluated, and the recommended dose was determined in phase I. The primary endpoint of the phase II analysis was overall survival rate at 1 year. Secondary endpoints were antitumour effects, symptom-relieving effects, safety and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The recommended doses of intravenous gemcitabine, intravenous nab-paclitaxel and intraperitoneal paclitaxel were 800, 75 and 20 mg\/m2 respectively. Among 46 patients enrolled in phase II, the median time to treatment failure was 6\u00b70 (range 0\u201322\u00b76) months. The response and disease control rates were 21 of 43 and 41 of 43 respectively. Ascites disappeared in 12 of 30 patients, and cytology became negative in 18 of 46. The median survival time was 14\u00b75 months, and the 1-year overall survival rate was 61 per cent. Conversion surgery was performed in eight of 46 patients, and those who underwent resection survived significantly longer than those who were not treated surgically (median survival not reached versus 12\u00b74 months). Grade 3\u20134 haematological toxicities developed in 35 of 46 patients, whereas non-haematological adverse events occurred in seven patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adding intraperitoneal paclitaxel had clinical efficacy with acceptable tolerability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bjs.11792","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:02:05Z","timestamp":1594166525000},"page":"1811-1817","source":"Crossref","is-referenced-by-count":57,"title":["Phase I\/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis"],"prefix":"10.1093","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-9119","authenticated-orcid":false,"given":"S","family":"Yamada","sequence":"first","affiliation":[{"name":"Gastroenterological Surgery, Nagoya University Graduate School of Medicine , Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Surgery and Science Faculty of Medicine, Academic Assembly, University of Toyama , Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7951-7429","authenticated-orcid":false,"given":"T","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kansai Medical University , Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Takami","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Nagoya University Graduate School of Medicine , Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Surgery and Science Faculty of Medicine, Academic Assembly, University of Toyama , Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Yamaki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kansai Medical University , Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Sonohara","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Nagoya University Graduate School of Medicine , Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Surgery and Science Faculty of Medicine, Academic Assembly, University of Toyama , Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Motoi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tohoku University Graduate School of Medicine , Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University , Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-3081","authenticated-orcid":false,"given":"Y","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary\u2013pancreatic and Breast Surgery, Ehime University Graduate School of Medicine , Ehime, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Nagoya University Graduate School of Medicine , Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Murotani","sequence":"additional","affiliation":[{"name":"Biostatistics Centre, Graduate School of Medicine, Kurume University , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kitayama","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Jichi Medical University , Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kodera","sequence":"additional","affiliation":[{"name":"Gastroenterological Surgery, Nagoya University Graduate School of Medicine , Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sekimoto","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kansai Medical University , Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-5409","authenticated-orcid":false,"given":"S","family":"Satoi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kansai Medical University , Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"2022100813010862500_bjs11792-bib-0001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPA.0b013e31825abf8c","article-title":"Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study","volume":"42","author":"Thomassen","year":"2013","journal-title":"Pancreas"},{"key":"2022100813010862500_bjs11792-bib-0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12957-016-0767-y","article-title":"A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma","volume":"14","author":"Satoi","year":"2016","journal-title":"World J Surg Oncol"},{"key":"2022100813010862500_bjs11792-bib-0003","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.1998.16.8.2620","article-title":"Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study","volume":"16","author":"Markman","year":"1998","journal-title":"J Clin Oncol"},{"key":"2022100813010862500_bjs11792-bib-0004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"2022100813010862500_bjs11792-bib-0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann Oncol"},{"key":"2022100813010862500_bjs11792-bib-0006","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jjco\/hyq187","article-title":"A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial)","volume":"41","author":"Kodera","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"2022100813010862500_bjs11792-bib-0007","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12029-014-9603-1","article-title":"Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis","volume":"45","author":"Takahara","year":"2014","journal-title":"J Gastrointest Cancer"},{"key":"2022100813010862500_bjs11792-bib-0008","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","article-title":"Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis","volume":"265","author":"Satoi","year":"2016","journal-title":"Ann Surg"},{"key":"2022100813010862500_bjs11792-bib-0009","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2022100813010862500_bjs11792-bib-0010","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s00534-013-0616-0","article-title":"Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery","volume":"20","author":"Satoi","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2022100813010862500_bjs11792-bib-0011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2022100813010862500_bjs11792-bib-0012","author":"Common Terminology Criteria for Adverse Event 4.0"},{"key":"2022100813010862500_bjs11792-bib-0013","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00280-018-3554-3","article-title":"Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer","volume":"81","author":"Yamada","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022100813010862500_bjs11792-bib-0014","volume-title":"NCCN Clinical Practice Guidelines in Oncology. NCCN: Plymouth Meeting, PA","author":"National Comprehensive Cancer Network (NCCN)","year":"2016"},{"key":"2022100813010862500_bjs11792-bib-0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000209277","article-title":"Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer","volume":"76","author":"Ishigami","year":"2009","journal-title":"Oncology"},{"key":"2022100813010862500_bjs11792-bib-0016","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin Plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022100813010862500_bjs11792-bib-0017","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/jjco\/hyq117","article-title":"Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study","volume":"40","author":"Shukuya","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"2022100813010862500_bjs11792-bib-0018","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archsurg.2011.152","article-title":"Downstaging chemotherapy and alteration in the classic computed tomography\/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery","volume":"146","author":"Donahue","year":"2011","journal-title":"Arch Surg"},{"key":"2022100813010862500_bjs11792-bib-0019","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"key":"2022100813010862500_bjs11792-bib-0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ags3.12295","article-title":"Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma","volume":"4","author":"Satoi","year":"2019","journal-title":"Ann Gastroenterol Surg"},{"key":"2022100813010862500_bjs11792-bib-0021","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","article-title":"Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"77","author":"Ueno","year":"2016","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.11792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/107\/13\/1811\/46392767\/bjs11792.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/107\/13\/1811\/46392767\/bjs11792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T09:37:21Z","timestamp":1665221841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/107\/13\/1811\/6139585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":21,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2020,7,7]]},"published-print":{"date-parts":[[2020,11,12]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.11792","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,7,7]]}}}